The best indicator for Amgen (AMGN)
We backtested 20 indicators across daily, weekly and hourly charts on real Amgen (AMGN) history. Here's what actually worked — risk-adjusted, out-of-sample, with costs.
EMA 50/200 Cross
On the daily chart, this is the strongest risk-adjusted edge we found for Amgen (AMGN) over ~43.0 years — trailing buy-and-hold by 5.0% CAGR.
The winner on each chart
Every indicator, ranked
Ranked by Sharpe (risk-adjusted return). Hypothetical, fees included.
| # | Indicator | TF | CAGR | Sharpe | Max DD | Win | Trades | vs B&H |
|---|---|---|---|---|---|---|---|---|
| 1 | EMA 50/200 Cross ✓ | Daily | 13.6% | 0.56 | -66.6% | 42.4% | 33 | -5.0% |
| 2 | EMA 20/50 Cross ✓ | Weekly | 12.8% | 0.54 | -70.3% | 50.0% | 24 | -5.7% |
| 3 | Donchian Breakout | Weekly | 11.1% | 0.54 | -55.8% | 48.6% | 35 | -7.4% |
| 4 | SMA 50/200 Cross ✓ | Daily | 11.9% | 0.53 | -69.4% | 38.9% | 36 | -6.7% |
| 5 | WaveTrend (8/6/4) ✓ | Weekly | 8.9% | 0.52 | -44.3% | 79.4% | 34 | -9.6% |
| 6 | Heikin-Ashi Trend ✓ | Weekly | 10.7% | 0.52 | -63.4% | 47.7% | 396 | -7.8% |
| 7 | EMA 20/50 Cross ✓ | Daily | 10.1% | 0.48 | -78.5% | 40.8% | 98 | -8.5% |
| 8 | Money Flow Index ✓ | Daily | 7.3% | 0.45 | -54.6% | 76.7% | 43 | -11.3% |
| 9 | RSI Trend (>50) | Weekly | 9.2% | 0.45 | -76.6% | 42.2% | 128 | -9.3% |
| 10 | Bollinger Mean-Reversion ✓ | Weekly | 5.6% | 0.45 | -41.6% | 72.4% | 29 | -12.9% |
| 11 | Stochastic ✓ | Daily | 7.9% | 0.44 | -69.3% | 68.1% | 213 | -10.7% |
| 12 | Donchian Breakout ✓ | Daily | 8.0% | 0.44 | -57.0% | 42.2% | 173 | -10.5% |
| 13 | Stochastic ✓ | Weekly | 6.6% | 0.43 | -44.3% | 81.0% | 42 | -11.9% |
| 14 | Donchian Midline | Weekly | 8.5% | 0.43 | -82.2% | 46.8% | 126 | -10.0% |
✓ = held up out-of-sample. Hypothetical, costs included. See methodology.
For Amgen (AMGN), EMA 50/200 Cross on the daily timeframe gave the best balance of return and risk in our test. It still trailed buy-and-hold on raw return — but remember: this is a hypothetical backtest of a standard rule, not a recommendation. Markets change. See the methodology and disclaimer.
More stock
Get the weekly edge report
The best-performing indicator per asset, what changed this week, and the honest caveats — straight to your inbox.